Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04932928

Patient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes Patients

We aim to provide medical nutritional therapy to patients with type 2 diabetes who are on oral hypoglycemic agents or on basal insulin only and monitor the glycemic response with flash glucose monitoring or self-monitoring of blood glucose.

Specifically, this is a randomized, open-label, controlled study where half of the study participants will have FreeStyle Libre device on for 12 weeks and compare the change in glycated hemoglobin (HbA1c) value with the patients in the control group.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Seoul National University Hospital

Seoul, 110-744, South Korea

Location status: Recruiting

Location contact

Young Min Cho, MD, PHD

CONTACT

[email protected]

82-2-2072-1965

About this study

Subjects: 126 patients with type 2 diabetes mellitus Scheme: Multi-center, Randomized, open-label, controlled study

This study is referred to as the "Patient-Driven lifestyle modification using FreeStyle Libre in type 2 diabetes patients", also known as the PDF study.

It will assess potential benefits of using Continuous Glucose Monitoring (CGM) versus Self Monitoring of Blood Glucose (SMBG) when combined with personalized education on lifestyle modification in people with type 2 diabetes. Specifically, we will investigate patients who have an elevated HbA1c between 7.0 - 10.0% who are not using prandial insulin.

Potential participants will be screened from routine outpatient clinic visits, will be randomized to either the CGM or SMBG group in a 1:1 ratio. Participants from both groups will receive education on lifestyle modification and will be reminded every 4 weeks with structured phone visits. Study will be completed at the visit on 12 weeks of follow up with the same laboratory examinations (including HbA1c) and survey from the baseline.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 19-80
  • Diagnosed with type 2 diabetes mellitus (DM)
  • Uncontrolled type 2 DM: HbA1c 7.0-10.0%
  • Signed informed consent

Exclusion criteria

  • Diagnosed with other types of diabetes mellitus (i.e. Type 1 DM)
  • Use of prandial insulin
  • Change in diabetes medication in the preceding 3 months
  • Pregnant/lactating women
  • Addiction to drugs and alcohol
  • Use of medications that result in drug-induced hyperglycemia (i.e. steroid)
  • Severe liver disease
  • End-stage renal disease (i.e. on dialysis)
  • Unable to wear CGM devices due to dermatologic side effects (i.e. severe burn, inflammation, active skin infection, severe skin reactions, hypertrichosis, etc.)
  • Conditions that impact the stability of HbA1c measurement

Treatment and study plan

Freestyle Libre

Device

Flash glucose monitoring + Education on lifestyle modification

Other names: Education on lifestyle modification

Blood glucose meter

Device

Self monitoring of blood glucose + Education on lifestyle modification

Other names: Education on lifestyle modification

Primary outcomes

  1. Change in HbA1c

    Time frame: Baseline to Month 3

    Between group differences (CGM and SMBG) for the change in HbA1c from baseline to Month 3

Secondary outcomes

  1. Change in mean fasting glucose

    Time frame: Baseline to Month 3

    Between group differences (CGM and SMBG) for the change in fasting glucose from baseline to Month 3

  2. Change in body weight

    Time frame: Baseline to Month 3

    Between group differences (CGM and SMBG) for the change in body weight from baseline to Month 3

  3. Change in blood pressure

    Time frame: Baseline to Month 3

    Between group differences (CGM and SMBG) for the change in blood pressure from baseline to Month 3

  4. Change in waist circumference

    Time frame: Baseline to Month 3

    Between group differences (CGM and SMBG) for the change in waist circumference from baseline to Month 3

  5. Change in lipid level

    Time frame: Baseline to Month 3

    Between group differences (CGM and SMBG) for the change in lipid level (total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol) from baseline to Month 3

  6. Change in the Korean Version of Revised Summary of Diabetes Self-Care Activities Questionnaire (SDSCA-K) survey score

    Time frame: Baseline to Month 3

    Between group differences (CGM and SMBG) for the change in survey score from baseline to Month 3

Other outcomes

  1. Change in CGM time in target range

    Time frame: Baseline to Month 3

    Change in CGM time in target range 70-180 mg/dL from baseline to Month 3 in the CGM group

  2. Change in CGM time-hyperglycemic

    Time frame: Baseline to Month 3

    Change in CGM time in time above target range, defined as >250 mg/dL from baseline to Month 3 in the CGM group

  3. Change in CGM time-hypoglycemic

    Time frame: Baseline to Month 3

    Change in CGM time in time below target range, defined as <70 mg/dL (level 1) and < 54 (level 2) from baseline to Month 3 in the CGM group

  4. Change in CGM glucose variability

    Time frame: Baseline to Month 3

    Change in CGM glucose variability measured by the coefficient of variation from baseline to Month 3 in the CGM group

Study contacts

Contact information is provided by the study sponsor or research team.

Hun Jee Choe, MD

CONTACT

[email protected]

82-2-2072-1965

Young Min Cho, MD, PhD

CONTACT

[email protected]

82-2-2072-1965

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Collaborators

  • Inje University
  • Kangbuk Samsung Hospital

Registry information

Acronym: PDF

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Jun 21, 2021
Registry last updated
Jun 21, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.